Bespak and Medicines Evaluation Unit Partners for Climate-Friendly Inhalers

Bespak and Medicines Evaluation Unit Partners for Climate-Friendly Inhalers

By, Admin 7 May 2024

Bespak and Medicines Evaluation Unit collaborate to accelerate clinical trials on climate-friendly inhalers

Overview

Bespak, a leading CDMO focussed on orally inhaled and nasal drug-device combination products, and The Medicines Evaluation Unit (MEU), one of the UK’s leading contract research organisations undertaking clinical trials in respiratory conditions, announced a collaboration to further accelerate the pharmaceutical industry’s transition from existing pressurised Metered Dose Inhaler (pMDI) formulations to climate-friendly alternatives utilising low global warming potential (GWP) propellants.

Impacts of Partnership

  • The partnership will align expert teams from the two organisations who will share knowledge and combine resources in order to fast-track time to clinic, and increase the throughput of low GWP pMDIs moving through clinical evaluation. 
  • Designed to service the increasing demand from pharmaceutical companies transitioning their inhaler portfolios to utilise the new generation of greener propellants, the collaboration will leverage Bespak’s clinical supply capabilities at its Holmes Chapel site to manufacture pMDIs containing the new propellants (HFA-152a and HFO-1234ze), for use in clinical studies to be conducted at the MEU. 
  • The collaboration also includes MEU’s Regulatory consultancy for clients to access as part of a package of services.

The companies will focus their activities with their teams working in close geographical proximity at their sites in the North West of England, well-known for its pMDI knowledge base and cluster of specialist pMDI companies such as Bespak.

Words from CEO: Bespak

Chris Hirst, CEO of Bespak, commented: “We are committed to leading the transition to low GWP propellants in pMDIs, and this collaboration with the highly respected MEU provides an accelerated route for our clients into clinical trials with more sustainable inhalers. At Bespak, we believe in working together across the industry to achieve a smooth transition that not only helps combat climate change, but also safeguards patient access to the familiar pMDI inhaler format.”

Words from CEO: MEU

David Rogers, CEO of MEU, said: “We are pleased to partner with Bespak to offer a fast pathway to the clinic for more sustainable inhalers using low GWP propellants. As two companies who have experience of the last environmentally-driven transition in pMDIs, we are pleased to bring together our services in a simplified pathway. Our joint aim is to enable more companies to enter this next phase in the development of greener inhalers, to benefit both patients and planet.”

MEU Work on Inhalers

  • The MEU is at the forefront of testing new climate-friendly inhalers to ensure they are safe and effective for large populations worldwide, and to support the transition towards low GWP propellants in pMDIs currently in development.
  • MEU led the testing of ozone friendly CFC-free inhalers that replaced CFC containing inhalers as a result of the Montreal Protocol on Substances that Deplete the Ozone Layer, adopted in 1987, and has already successfully conducted clinical studies into the investigation of both of the new low GWP propellants in development.  

Bespak’s Holmes Chapel Site

  • Bespak’s Holmes Chapel site has a long history in the development, scale-up and clinical and commercial supply of inhalers going back to the 1960s. 
  • This most recent announcement builds upon Bespak’s recent news including its spin-out from the Recipharm Group to create an independent company focused on inhaled and nasal drug-device combination products; its significant investment in commercial-scale and pilot-scale filling equipment for the manufacture of pMDIs using low GWP propellant HFA-152a at its Holmes Chapel site; and the site’s landmark milestone last year as it became the first CDMO to manufacture a pMDI at commercial scale with HFO-1234ze, a near-zero GWP propellant.

Bespak

  • Bespak is a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery devices and drug-device combination products.
  • Bespak develops and manufactures finished pharmaceutical products, as well as being a leading global supplier of drug delivery devices and componentry to the pharmaceutical industry.

The Medicines Evaluation Unit

  • The Medicines Evaluation Unit (MEU) Ltd is one of the UK’s leading contract research organisations, a facility where commitment to excellence is paramount.
  • The MEU is recognised as one of the leading sites to undertake clinical trials in respiratory conditions, including asthma, COPD, IPF, CF and NCFB, having carried out over 350 studies in this area.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!